Results 101 to 110 of about 27,891 (313)

Bioinorganic Site‐Specific Conjugation of Multi‐Arm Linkers to Create Pharmaceuticals With Targeting and Effector Functions

Journal of the Chinese Chemical Society, EarlyView.
This Account showcases a modular, multi‐arm linker platform that decouples payload loading from antibody conjugation. By leveraging a computationally designed ACPGHA zinc‐binding motif, we demonstrate the construction of homogeneous antibody‐drug conjugates and theranostic antibody‐radionuclide conjugates with high payload loading. The multi‐arm linker
Cédric Grauffel, Tse Wen Chang, Carmay Lim   +2 more
wiley   +1 more source

Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis

Frontiers in Pharmacology
ObjectiveThe incidence of ischemic cardiomyopathy increases annually worldwide, and it is the leading cause of mortality in China. Although interventional diagnostic and therapeutic techniques can promptly open the culprit vessels, myocardial ischemia ...
Yan Liu, Zixuan Li, Xinhe Xu, Yan Zou, Miaomiao Zhang, Yingyu Chen, Wenwu Zhu, Bing Han   +7 more
doaj   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source

Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5/NR4a1 axis

Nature Communications
Semaglutide, a glucagon-like peptide-1 receptor agonist, is clinically used as a glucose-lowering and weight loss medication due to its effects on energy metabolism.
Yu-Lan Ma, Chun-Yan Kong, Zhen Guo, Ming-Yu Wang, Pan Wang, Fang-Yuan Liu, Dan Yang, Zheng Yang, Qi-Zhu Tang   +8 more
doaj   +1 more source

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, Maya Halabi‐Tawil
wiley   +1 more source

Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

, 2017
BACKGROUND : Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and elevated ...
CANVAS Program Collaborative Group, De Zeeuw, D, Desai, M, Erondu, N, Fabbrini, E, Fulcher, G, Li, Q, Mahaffey, KW, Matthews, DR, Neal, B, Perkovic, V, Shaw, W, Sun, T   +12 more
core   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes.

PLoS ONE
BackgroundType 2 diabetes mellitus (T2DM) is associated with cognitive dysfunction, which significantly impacts the quality of life. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown potential neuroprotective effects.
Yan Zhu, Yi He, Hongyan Yang, Yanbo Gao, Yan Wang, Peiqing Liu, Mengjuan Zhang   +6 more
doaj   +1 more source

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial [PDF]

BACKGROUND Patients with overweight and obesity are at increased risk of death from multiple causes, including cardiovascular (CV) death, with few therapies proven to reduce the risk. OBJECTIVES This study sought to assess the effect of semaglutide 2.4
Bogdanski P., Buscemi S., Colhoun H., Craciun A. E., Deanfield J., Ezhov M., Hardt-Lindberg S., Kleist Jeppesen O., Lincoff A. M., Lingvay I., Matos A. L. S. A., Node K., Ryan D., Schiele F., Scirica B. M., Toplak H., van Beek A., Weeke P. E., Wiviott S. D.   +18 more
core   +4 more sources

Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults

JAMA Health Forum
Key Points Question What are the lifetime health effects and cost-effectiveness of different antiobesity medications compared with lifestyle modification in the US population? Findings In this economic evaluation of 4 antiobesity medications, tirzepatide
Jennifer H Hwang, N. Laiteerapong, Elbert S. Huang, David D. Kim   +3 more
semanticscholar   +1 more source